BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 26941094)

  • 1. Anti-Tumoral Effects of Anti-Progestins in a Patient-Derived Breast Cancer Xenograft Model.
    Esber N; Cherbonnier C; Resche-Rigon M; Hamze A; Alami M; Fagart J; Loosfelt H; Lombès M; Chabbert-Buffet N
    Horm Cancer; 2016 Apr; 7(2):137-47. PubMed ID: 26941094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new strategy for selective targeting of progesterone receptor with passive antagonists.
    Khan JA; Tikad A; Fay M; Hamze A; Fagart J; Chabbert-Buffet N; Meduri G; Amazit L; Brion JD; Alami M; Lombès M; Loosfelt H; Rafestin-Oblin ME
    Mol Endocrinol; 2013 Jun; 27(6):909-24. PubMed ID: 23579486
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ulipristal Acetate Inhibits Progesterone Receptor Isoform A-Mediated Human Breast Cancer Proliferation and BCl2-L1 Expression.
    Esber N; Le Billan F; Resche-Rigon M; Loosfelt H; Lombès M; Chabbert-Buffet N
    PLoS One; 2015; 10(10):e0140795. PubMed ID: 26474308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progesterone receptor antagonism inhibits progestogen-related carcinogenesis and suppresses tumor cell proliferation.
    Lee O; Choi MR; Christov K; Ivancic D; Khan SA
    Cancer Lett; 2016 Jul; 376(2):310-7. PubMed ID: 27080304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progestin effects on breast cancer cell proliferation, proteases activation, and in vivo development of metastatic phenotype all depend on progesterone receptor capacity to activate cytoplasmic signaling pathways.
    Carnevale RP; Proietti CJ; Salatino M; Urtreger A; Peluffo G; Edwards DP; Boonyaratanakornkit V; Charreau EH; Bal de Kier Joffé E; Schillaci R; Elizalde PV
    Mol Endocrinol; 2007 Jun; 21(6):1335-58. PubMed ID: 17440047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The estrogenic activity of synthetic progestins used in oral contraceptives enhances fatty acid synthase-dependent breast cancer cell proliferation and survival.
    Menendez JA; Oza BP; Colomer R; Lupu R
    Int J Oncol; 2005 Jun; 26(6):1507-15. PubMed ID: 15870863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estrogen receptor alpha mediates progestin-induced mammary tumor growth by interacting with progesterone receptors at the cyclin D1/MYC promoters.
    Giulianelli S; Vaqué JP; Soldati R; Wargon V; Vanzulli SI; Martins R; Zeitlin E; Molinolo AA; Helguero LA; Lamb CA; Gutkind JS; Lanari C
    Cancer Res; 2012 May; 72(9):2416-27. PubMed ID: 22396492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breast Cancer Suppression by Progesterone Receptors Is Mediated by Their Modulation of Estrogen Receptors and RNA Polymerase III.
    Finlay-Schultz J; Gillen AE; Brechbuhl HM; Ivie JJ; Matthews SB; Jacobsen BM; Bentley DL; Kabos P; Sartorius CA
    Cancer Res; 2017 Sep; 77(18):4934-4946. PubMed ID: 28729413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proliferation and ovarian hormone signaling are impaired in normal breast tissues from women with BRCA1 mutations: benefit of a progesterone receptor modulator treatment as a breast cancer preventive strategy in women with inherited BRCA1 mutations.
    Communal L; Vilasco M; Hugon-Rodin J; Courtin A; Mourra N; Lahlou N; Le Guillou M; Perrault de Jotemps M; Chauvet MP; Chaouat M; Pujol P; Feunteun J; Delaloge S; Forgez P; Gompel A
    Oncotarget; 2016 Jul; 7(29):45317-45330. PubMed ID: 27246982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Downregulation of the tumor-suppressor miR-16 via progestin-mediated oncogenic signaling contributes to breast cancer development.
    Rivas MA; Venturutti L; Huang YW; Schillaci R; Huang TH; Elizalde PV
    Breast Cancer Res; 2012 May; 14(3):R77. PubMed ID: 22583478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ulipristal acetate does not impact human normal breast tissue.
    Communal L; Vilasco M; Hugon-Rodin J; Courtin A; Mourra N; Lahlou N; Dumont S; Chaouat M; Forgez P; Gompel A
    Hum Reprod; 2012 Sep; 27(9):2785-98. PubMed ID: 22740493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progesterone metabolites regulate induction, growth, and suppression of estrogen- and progesterone receptor-negative human breast cell tumors.
    Wiebe JP; Zhang G; Welch I; Cadieux-Pitre HA
    Breast Cancer Res; 2013 May; 15(3):R38. PubMed ID: 25927181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gonadotropin-releasing hormone type II antagonist induces apoptosis in MCF-7 and triple-negative MDA-MB-231 human breast cancer cells in vitro and in vivo.
    Gründker C; Föst C; Fister S; Nolte N; Günthert AR; Emons G
    Breast Cancer Res; 2010; 12(4):R49. PubMed ID: 20630060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective progesterone receptor blockade prevents BRCA1-associated mouse mammary tumors through modulation of epithelial and stromal genes.
    Lee O; Bosland MC; Wang M; Shidfar A; Hosseini O; Xuei X; Patel P; Schipma MJ; Helenowski I; Kim JJ; Clare SE; Khan SA
    Cancer Lett; 2021 Nov; 520():255-266. PubMed ID: 34329741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanism of Telapristone Acetate (CDB4124) on Progesterone Receptor Action in Breast Cancer Cells.
    Davaadelger B; Murphy AR; Clare SE; Lee O; Khan SA; Kim JJ
    Endocrinology; 2018 Oct; 159(10):3581-3595. PubMed ID: 30203004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FGF2 induces breast cancer growth through ligand-independent activation and recruitment of ERα and PRBΔ4 isoform to MYC regulatory sequences.
    Giulianelli S; Riggio M; Guillardoy T; Pérez Piñero C; Gorostiaga MA; Sequeira G; Pataccini G; Abascal MF; Toledo MF; Jacobsen BM; Guerreiro AC; Barros A; Novaro V; Monteiro FL; Amado F; Gass H; Abba M; Helguero LA; Lanari C
    Int J Cancer; 2019 Oct; 145(7):1874-1888. PubMed ID: 30843188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progesterone receptor modulates ERα action in breast cancer.
    Mohammed H; Russell IA; Stark R; Rueda OM; Hickey TE; Tarulli GA; Serandour AA; Birrell SN; Bruna A; Saadi A; Menon S; Hadfield J; Pugh M; Raj GV; Brown GD; D'Santos C; Robinson JL; Silva G; Launchbury R; Perou CM; Stingl J; Caldas C; Tilley WD; Carroll JS
    Nature; 2015 Jul; 523(7560):313-7. PubMed ID: 26153859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein kinases mediate ligand-independent derepression of sumoylated progesterone receptors in breast cancer cells.
    Daniel AR; Lange CA
    Proc Natl Acad Sci U S A; 2009 Aug; 106(34):14287-92. PubMed ID: 19706513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progesterone promotes immunomodulation and tumor development in the murine mammary gland.
    Werner LR; Gibson KA; Goodman ML; Helm DE; Walter KR; Holloran SM; Trinca GM; Hastings RC; Yang HH; Hu Y; Wei J; Lei G; Yang XY; Madan R; Molinolo AA; Markiewicz MA; Chalise P; Axelrod ML; Balko JM; Hunter KW; Hartman ZC; Lange CA; Hagan CR
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33958486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progestin-mediated activation of MAPK and AKT in nuclear progesterone receptor negative breast epithelial cells: The role of membrane progesterone receptors.
    Salazar M; Lerma-Ortiz A; Hooks GM; Ashley AK; Ashley RL
    Gene; 2016 Oct; 591(1):6-13. PubMed ID: 27349565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.